ArticleFrontiers in oncology2025
Hilar cholangiocarcinoma patients accepting preoperative percutaneous transhepatic biliary drainage experienced high incidence of portal vein invasion and lymph node metastasis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Percutaneous transhepatic biliary drainage (PTBD) was widely used for bile drainage in hilar cholangiocarcinoma (HCCA) patients, due to its exact effectiveness in relieving obstructive jaundice. However, the potential association between PTBD and increased local tumor spread (including portal vein invasion and lymph node metastasis) remained unclear, as this procedure might prolong the waiting time and lead to potential risks of portal vein injury. This study aimed to investigate whether HCCA patients undergoing PTBD exhibit higher risks of portal vein invasion and lymph node metastasis after radical resection. Methods: The clinical data of 341 HCCA patients was retrospectively analyzed. PTBD was exclusively used as the preoperative biliary drainage method, excluding patients who underwent endoscopic nasobiliary drainage or endoscopic biliary stenting. Portal vein invasion and lymph node metastasis were verified by postoperative pathological examinations. Results: In this study, 163 patients (47.8%) received preoperative PTBD. These patients experienced significantly higher risks of portal vein invasion [odds ratio (OR): 1.86, p = 0.027] and lymph node metastasis (OR: 1.94, p = 0.008) compared to those 178 patients (52.2%) in the non-PTBD group. The Kaplan-Meier survival analysis revealed significantly better OS (p = 0.039) in the non-PTBD group. Causal mediation analysis revealed that the effect of PTBD on survival was partly mediated by portal vein invasion and lymph node metastasis. Additionally, the length of hospitalization in PTBD group was obviously longer (26.7 days vs. 21.8 days, p = 0.002). Conclusion: Preoperative PTBD was associated with increased incidence of portal vein invasion and lymph node metastasis in HCCA patients accepting R0 resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.